Evaluation of Gene Expression Data From Cybrids and Tumours Highlights Elevated
NDRG1
breast cancer
cybrids
Journal
Breast cancer : basic and clinical research
ISSN: 1178-2234
Titre abrégé: Breast Cancer (Auckl)
Pays: United States
ID NLM: 101474356
Informations de publication
Date de publication:
2020
2020
Historique:
received:
27
03
2020
accepted:
20
05
2020
entrez:
3
7
2020
pubmed:
3
7
2020
medline:
3
7
2020
Statut:
epublish
Résumé
Triple-negative breast cancer is an aggressive type of breast cancer with high risk of recurrence. It is still poorly understood and lacks any targeted therapy, which makes it difficult to treat. Thus, it is important to understand the underlying mechanisms and pathways that are dysregulated in triple-negative breast cancer. To investigate the role of mitochondria in triple-negative breast cancer progression, we analysed previously reported gene expression data from triple-negative breast cancer cybrids with SUM-159 as the nuclear donor cell and SUM-159 or A1N4 (c-SUM-159, c-A1N4) as the mitochondrial donor cells and with 143B as the nuclear donor cell and MCF-10A or MDA-MB-231 (c-MCF-10A, c-MDA-MB-231) as the mitochondrial donor cells. The role of potential biomarkers in cell proliferation and migration was examined in SUM-159 and MDA-MB-231 cells using sulforhodamine B and wound healing assays. Rank product analysis of cybrid gene expression data identified 149 genes which were significantly up-regulated in the cybrids with mitochondria from the cancer cell line. Analysis of previously reported breast tumour gene expression datasets confirmed 9 of the 149 genes were amplified, up-regulated, or down-regulated in more than 10% of the patients. The genes included These results indicate that mitochondria-regulated nuclear gene expression helps breast cancer cells survive and proliferate, consistent with previous work focusing on an Src gene signature which is mitochondria regulated and drives malignancy in breast cancer cybrids. This is the first study to show that mitochondria in triple-negative breast cancer mediate significant up-regulation of a number of genes, and silencing of
Sections du résumé
BACKGROUND
BACKGROUND
Triple-negative breast cancer is an aggressive type of breast cancer with high risk of recurrence. It is still poorly understood and lacks any targeted therapy, which makes it difficult to treat. Thus, it is important to understand the underlying mechanisms and pathways that are dysregulated in triple-negative breast cancer.
METHODS
METHODS
To investigate the role of mitochondria in triple-negative breast cancer progression, we analysed previously reported gene expression data from triple-negative breast cancer cybrids with SUM-159 as the nuclear donor cell and SUM-159 or A1N4 (c-SUM-159, c-A1N4) as the mitochondrial donor cells and with 143B as the nuclear donor cell and MCF-10A or MDA-MB-231 (c-MCF-10A, c-MDA-MB-231) as the mitochondrial donor cells. The role of potential biomarkers in cell proliferation and migration was examined in SUM-159 and MDA-MB-231 cells using sulforhodamine B and wound healing assays.
RESULTS
RESULTS
Rank product analysis of cybrid gene expression data identified 149 genes which were significantly up-regulated in the cybrids with mitochondria from the cancer cell line. Analysis of previously reported breast tumour gene expression datasets confirmed 9 of the 149 genes were amplified, up-regulated, or down-regulated in more than 10% of the patients. The genes included
CONCLUSIONS
CONCLUSIONS
These results indicate that mitochondria-regulated nuclear gene expression helps breast cancer cells survive and proliferate, consistent with previous work focusing on an Src gene signature which is mitochondria regulated and drives malignancy in breast cancer cybrids. This is the first study to show that mitochondria in triple-negative breast cancer mediate significant up-regulation of a number of genes, and silencing of
Identifiants
pubmed: 32612361
doi: 10.1177/1178223420934447
pii: 10.1177_1178223420934447
pmc: PMC7309340
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1178223420934447Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Declaration of conflicting interests:The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Cell Rep. 2016 Mar 8;14(9):2154-2165
pubmed: 26923594
Nucleic Acids Res. 2005 Nov 10;33(20):e175
pubmed: 16284200
Oncogene. 2007 Mar 22;26(13):1959-70
pubmed: 17001317
Cell Res. 2018 Mar;28(3):265-280
pubmed: 29219147
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Genome Biol. 2004;5(10):R80
pubmed: 15461798
Neuromuscul Disord. 2007 Feb;17(2):163-8
pubmed: 17142040
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Biochim Biophys Acta. 2010 Jan;1797(1):29-37
pubmed: 19647716
FEBS Lett. 2004 Aug 27;573(1-3):83-92
pubmed: 15327980
Tumour Biol. 2011 Dec;32(6):1271-6
pubmed: 21909787
Nat Commun. 2016 May 10;7:11479
pubmed: 27161491
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
PLoS One. 2013 May 09;8(5):e61747
pubmed: 23671572
Breast Cancer Res. 2018 Jun 14;20(1):55
pubmed: 29898756